Antiplatelets (P2Y12 inhibitors)
- Platelet ADP-receptor blockers
- ACS/PCI + secondary atherothrombosis
- Clopidogrel: common; needs CYP2C19
- Prasugrel: potent; avoid prior stroke/TIA
- Ticagrelor: potent/reversible; dyspnea
- Bleeding is the class-defining toxicity
- Usually paired with aspirin after PCI/ACS
Class at a glance
- Platelet ADP-receptor blockers
Safety / monitoring
- Clopidogrel: common; needs CYP2C19
- Prasugrel: potent; avoid prior stroke/TIA
- Ticagrelor: potent/reversible; dyspnea
Practical pearls
- ACS/PCI + secondary atherothrombosis
- Usually paired with aspirin after PCI/ACS
Safety distinctions
- Bleeding is the class-defining toxicity
Self-check
- How does Antiplatelets (P2Y12 inhibitors) work?
Platelet ADP-receptor blockers. - What distinguishes Prasugrel?
Potent; avoid prior stroke/TIA.
Drugs in this class (5)
Antiplatelets (P2Y12 inhibitors) prescription history
Animated chart of estimated U.S. prescriptions per year, Antithrombotics (1914–2026). P2Y12 inhibitors highlighted from 1991.
All drug classes · Open Antiplatelets (P2Y12 inhibitors) in the interactive console ↗